TiGenix

its Alofisel (darvadstrocel) is an EU-approved allogeneic MSC for complex perianal fistulas in adult Crohn's disease, and Takeda provides periodic updates on the programme as the EU's lead commercial autoimmune-MSC asset.

Country: Spain

Commercial MSC (darvadstrocel / Alofisel)

Coverage

	CN	EU	US
therapeutics-platforms	✓	✓	✓

Regulatorsfdaemanmpa

Verifiable facts

Fact	Value	Source
Funding	Takeda acquired TiGenix in 2018 for approximately €520 million	talent24h.okdiario.com
Capacity	Production capacity in Spain was tripled following a €10.6 million investment in 2021	gacetamedica.com · takeda.com
Regulatory approval	Alofisel received European Commission marketing authorization in March 2018	prnewswire.com · takeda.com
Production site	Manufacturing plant located in Tres Cantos, Madrid, which closed following the cessation of Alofisel production in 2026	gacetamedica.com · talent24h.okdiario.com · redaccionmedica.com · takeda.com
Headcount	The Tres Cantos facility employed approximately 120 people as of February 2026	madridinforma.eldiario.es · talent24h.okdiario.com · redaccionmedica.com
Revenue	Takeda reported annual sales of 4.26 trillion yen for 2024	madridinforma.eldiario.es · talent24h.okdiario.com

Independent sources: gacetamedica.com · madridinforma.eldiario.es · prnewswire.com · redaccionmedica.com · takeda.com · talent24h.okdiario.com

Technologies

Name	Cluster	Risk
Stem cell therapy for autoimmune disease	therapeutics-platforms	Medium	→

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.